Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis C

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 45 articles: HTML format

Single Articles

July 2025
1. SANDMANN L
   From HCV to HEV: Repurposing a nucleoside analogue for hepatitis E therapy.
   J Hepatol. 2025 Jul 31:S0168-8278(25)02322-0. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   April 2025
2. HOUGHTON M
   A rat hepacivirus model to aid hepatitis C viral vaccine development ?
   J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
3. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
   Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
   J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
4. LUHMANN N, Wedemeyer H
   More than 10 years of IFN-free HCV treatment and viral hepatitis elimination: Mission not completed!
   J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
5. JIN F, Gridley J, Kumari A, Saeidi A, et al
   Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.
   J Hepatol. 2025;82:604-614.
   PubMed     Abstract available
   
   
   March 2025
6. THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al
   Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host evolution and escape from neutralizing antibodies.
   J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   
7. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
   Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
   J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   February 2025
8. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
   Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
   J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   
9. RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al
   Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
   J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   December 2024
10. WANG C, Tian H, Shang J
    Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    October 2024
11. LIU CH, Cheng PN, Fang YJ, Chen CY, et al
    Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
    J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
12. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
    Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    J Hepatol. 2024;81:590-599.
    PubMed     Abstract available
    
    
    September 2024
13. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    August 2024
14. KIM SY, Shin EC
    Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C treatment".
    J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    July 2024
15. SOLIMAN R, Hassan A, Shiha G
    Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
    J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
16. MINAMI T, Fujishiro M, Tateishi R
    Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score".
    J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
17. KUNDU J, Le HT, Logan M, Hockman D, et al
    Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
    J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    June 2024
18. KIM SY, Koh JY, Lee DH, Kim HD, et al
    Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    May 2024
19. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
    EASL position paper on clinical follow-up after HCV cure.
    J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
20. SHIHA G, Mikhail N, Soliman R
    Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
    J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    April 2024
21. KENNEDY MJ, Fernbach S, Scheel TKH
    Animal hepacivirus models for hepatitis C virus immune responses and pathology.
    J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
22. UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al
    B cell characteristics define HCV reinfection outcome.
    J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    March 2024
23. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
24. SHEEHAN Y, Grebely J, Lloyd AR
    Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    J Hepatol. 2024;80:e107-e108.
    PubMed    
    
    
    February 2024
25. BIALLAS R, Zimmermann R, Dudareva S
    Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
    J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
26. LIU C, Guo C, Liu K
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    January 2024
27. HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al
    Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study.
    J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
28. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
29. THOMPSON LA, Charlton CL
    Evaluation and comparison of risk-based and universal HCV screening programs.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    November 2023
30. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    August 2023
31. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    July 2023
32. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    June 2023
33. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
34. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
35. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    May 2023
36. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    April 2023
37. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
38. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
39. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
40. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
41. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    March 2023
42. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
43. CUI A, Li B, Wallace MS, Gonye ALK, et al
    Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
    J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
44. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
45. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.